SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Visit website
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS
BioCapital
The 12 Days of Christmas, Biopharma Style
To help kick off the holiday season, BioSpace gave this Christmas classic a unique biopharma spin.
December 9, 2019
 · 
8 min read
 · 
Mark Terry and Alex Keown
Business
Communicating Diversity and Inclusion: 5 Life Sciences Companies Who Are Nailing It
Here are five high-quality examples of major bio organizations’ efforts to showcase their commitment to providing a positive D&I work environment.
December 2, 2019
 · 
5 min read
 · 
Dana Dunbar, Career Branding Strategist
Business
AbbVie and Harpoon Expand Partnership with $510 Million Licensing Deal
The new deal builds on a discovery agreement signed in October 2017.
November 21, 2019
 · 
2 min read
 · 
Mark Terry
Business
Dragonfly Partners With AbbVie to Take on Autoimmune and Oncology Indications
At the center of the agreement are Dragonfly’s novel NK cell engager-based immunotherapies.
November 20, 2019
 · 
2 min read
 · 
Alex Keown
Drug Development
Inflammatory Bowel Disease Insight Report: Current Therapies, Drug Pipeline and Outlook
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
November 18, 2019
 · 
33 min read
 · 
Tracy Lawton
BioCapital
Clinical Catch-Up: November 11-15
It was a busy week for clinical trial announcements. Here’s a look.
November 15, 2019
 · 
12 min read
 · 
Mark Terry
Genetown
New Pharma Invention Index Picks AstraZeneca as Top Company
The newly-launched index takes a focused look at the breadth and depth of novel agents currently being developed within the most innovative pharmaceutical pipelines.
November 5, 2019
 · 
3 min read
 · 
Alex Keown
Business
Liquidia Technologies Appoints Industry Veteran Katie Rielly-Gauvin to Board of Directors
Liquidia Technologies, Inc. announced the appointment of Katie Rielly-Gauvin, Vice President of Global Commercial Development at AbbVie, to the Company’s Board of Directors as a Class II director with a term expiring at the 2020 annual meeting of stockholders and to the Company’s Research and Development Committee and Nominating & Governance Committee.
November 3, 2019
 · 
4 min read
Drug Development
AbbVie’s Rinvoq Likely Headed for Another Approval in a Crowded Inflammatory Market
On the same day Novartis announced that its Cosentyx didn’t prove itself superior to AbbVie’s Humira in psoriatic arthritis, AbbVie announced that its Rinvoq met the primary endpoint in active psoriatic arthritis in its SELECT-PsA 2 Phase III trial.
November 1, 2019
 · 
2 min read
 · 
Mark Terry
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
Deals
AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma
June 24, 2021
 · 
5 min read
Business
AbbVie Declares Quarterly Dividend - June 17, 2021
June 17, 2021
 · 
1 min read
Business
Zhongchao Inc. Partners with a Subsidiary of AbbVie Inc. (NYSE: ABBV) for Medical Education Services
June 16, 2021
 · 
3 min read
Drug Development
IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia (CLL) Phase 3 GLOW Study
June 12, 2021
 · 
29 min read
Drug Development
New Data Shows AbbVie’s VENCLYXTO®/VENCLEXTA® Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment
June 11, 2021
 · 
15 min read
Business
Caraway Therapeutics Establishes Collaboration with AbbVie to Develop Novel Small Molecule Therapeutics for Parkinson’s Disease and Other Related Disorders
June 9, 2021
 · 
3 min read
Biotech Beach
Allergan Aesthetics and BOTOX® Cosmetic (onabotulinumtoxinA) Put Real Stories at the Forefront in New Campaign
June 8, 2021
 · 
9 min read
Drug Development
CAPTIVATE Study Shows an IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for Chronic Lymphocytic Leukemia (CLL)
June 7, 2021
 · 
27 min read
Drug Development
Results from IMBRUVICA® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)
June 4, 2021
 · 
15 min read
BioMidwest
AbbVie to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
June 2, 2021
 · 
1 min read
Load More